- Home
- IBCP vs CVAC Comparison
IBCP vs CVAC Comparison
Compare IBCP & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBCP
- CVAC
- Stock Information
- Founded
- IBCP 1864
- CVAC 2000
- Country
- IBCP United States
- CVAC Germany
- Employees
- IBCP N/A
- CVAC N/A
- Industry
- IBCP Major Banks
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- IBCP Finance
- CVAC Health Care
- Exchange
- IBCP Nasdaq
- CVAC Nasdaq
- Market Cap
- IBCP 795.2M
- CVAC 637.1M
- IPO Year
- IBCP N/A
- CVAC 2020
- Fundamental
- Price
- IBCP $37.74
- CVAC $2.54
- Analyst Decision
- IBCP Hold
- CVAC Hold
- Analyst Count
- IBCP 3
- CVAC 3
- Target Price
- IBCP $32.17
- CVAC $10.00
- AVG Volume (30 Days)
- IBCP 111.9K
- CVAC 540.3K
- Earning Date
- IBCP 10-24-2024
- CVAC 11-12-2024
- Dividend Yield
- IBCP 2.54%
- CVAC N/A
- EPS Growth
- IBCP 3.52
- CVAC N/A
- EPS
- IBCP 2.94
- CVAC N/A
- Revenue
- IBCP $208,212,000.00
- CVAC $70,565,734.00
- Revenue This Year
- IBCP N/A
- CVAC $123.97
- Revenue Next Year
- IBCP $5.96
- CVAC N/A
- P/E Ratio
- IBCP $12.84
- CVAC N/A
- Revenue Growth
- IBCP 3.25
- CVAC 75.11
- 52 Week Low
- IBCP $20.50
- CVAC $2.22
- 52 Week High
- IBCP $39.52
- CVAC $6.30
- Technical
- Relative Strength Index (RSI)
- IBCP 63.08
- CVAC 34.97
- Support Level
- IBCP $31.79
- CVAC $2.73
- Resistance Level
- IBCP $39.52
- CVAC $2.97
- Average True Range (ATR)
- IBCP 1.20
- CVAC 0.18
- MACD
- IBCP 0.38
- CVAC -0.01
- Stochastic Oscillator
- IBCP 76.97
- CVAC 7.55
About IBCP Independent Bank Corporation
Independent Bank Corp (Ionia MI) operates as a commercial bank. It offers a broad range of banking services to individuals and businesses, including checking and savings accounts, commercial lending, direct and indirect consumer financing, mortgage lending, and safe deposit box services. It also provides internet and mobile banking capabilities to its customers.
About CVAC CureVac N.V.
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.